CILO CYBIN HOLDINGS LIMITED
(Incorporated in South Africa)
Registration number 2022/320351/06
Cilo Cybin Holdings Limited, is a South African incorporated legal entity that is in the process of going public on the Johannesburg Stock Exchange. To date we have appointed all the various parties that will assist us in this process, see below.
This page is to provide a high level overview of Cilo Cybin Holdings, as well as more information on the Special Purpose Acquisition Company (SPAC) that will be doing an Initial Public Offering (IPO) shortly. Make sure that your name is on our investor list in order to be notified as soon as the Prospectus is available.
Independent Reporting Accountants
Company Legal Advisor
JSE Investor Services
The Company will combine businesses within the Biohacking, Biotech, and Pharmaceutical methodologies to deliver a holistic and legalised solution, through Artificial Intelligence, that will enable its customers’ insights into their health, performance, and longevity, that they never had before.
We believe the world is entering a new era of personalised healthcare, a world in which each person’s health and wellbeing will require bespoke, individualised and intelligently targeted interventions.
Cilo Cybin is ready and able to successfully propel its product and service offering to a world that continues to hope and strive for better health, performance, and longevity.
In terms of the JSE Listings Requirements, the Company must Complete an acquisition of Viable Assets within the Initial Period. The acquisition of Viable Assets must be approved by a majority of disinterested Directors and by an ordinary resolution of Shareholders at a general meeting.
The Viable Assets, which will be managed by the Company following their acquisition, may include direct or indirect investments in projects and/or businesses whose purpose is to cultivate, manufacture, analyse, distribute, or retail in any of the pharmaceutical, biotech or biohacking industries, and in respect of which the Board has identified an opportunity to enhance the combined offering of the complete service and product offering of the Company with the goal to improve profitability, thereby maximising Shareholder return.
While the Company’s efforts in identifying prospective Viable Assets will not be limited to a particular industry or geographic region, locally or internationally, the Company expects to also acquire a controlling interest in a Company or business in the Cannabis industry.
The Company will combine businesses within the Biohacking, Biotech, and Pharmaceutical methodologies to deliver a holistic and legalized solution that will enable its customers’ insights into their health, performance, and longevity, that they never had before.
What is Biotech & Pharmaceutical:
Biotechnology and pharmaceutical companies both produce medicines, but the medicines made by biotechnology companies are derived from living organisms while those made by pharmaceutical companies generally have a chemical basis.
What is Biohacking:
Biohacking is the constant pursuit of better health, performance, and longevity using technologies, apps, devices, and supplementation
Data is the future of medical care and preventative healthcare. Having access to patient’s genetic, lab and symptom data can be the start of heath discoveries that we can only dream of today.
Today we can easily assist certain genetic mutations with health supplements, this is considered to be mainstream, tomorrow we can alter genetics permanently.
Register here in order to be the first to receive access to pre order products.